Form 4: Sutro Biopharma Director Granted Stock Options

Sutro Biopharma Director Sukhi Jagpal was granted 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.

Summary

• Sukhi Jagpal, a Director of Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
• The stock options have an exercise price of $10.38 per share.
• The options were granted on December 23, 2025, and expire on December 23, 2035.
• The options will vest as to 16.67% of the total award monthly, subject to continued service to the issuer.
• The first vesting tranche is scheduled for January 23, 2026.
• Following this transaction, Sukhi Jagpal beneficially owns 1,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation event for a director. It is generally positive as it aligns the director's interests with shareholders but does not provide new material information about the company's operational or financial performance.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Sutro Biopharma, Inc.
• Equity compensation is a standard practice to attract and retain qualified directors and executives.

Negatives

• The value of the options is contingent on the future stock price exceeding the exercise price, meaning there is no guaranteed immediate financial gain.
• This transaction does not represent a direct cash investment by the director into the company's equity.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Sutro Biopharma's common stock.
• If the company's stock price does not rise above the exercise price of $10.38, the options may expire worthless.

Future Outlook

The grant of stock options to a director is a standard component of executive compensation, indicating an expectation of continued service and alignment with long-term company performance. The vesting schedule encourages sustained commitment.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, where long-term value creation and retention of key personnel are critical. This form of compensation is widely used to incentivize leadership to drive innovation and achieve strategic milestones.

Comparison to Industry Standards

• The use of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly within growth-oriented sectors like biotechnology.
• The vesting schedule, typically over several years, is consistent with industry norms designed to promote long-term commitment and performance.
• While specific grant sizes vary by company size, director responsibilities, and overall compensation philosophy, the structure of this equity award aligns with general market practices for non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Sukhi Jagpal, a Director of Sutro Biopharma, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The option grant aligns the director's incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated by this filing, but it reflects the company's compensation philosophy for leadership.
• Management: The Power of Attorney simplifies SEC reporting for the director and the company's legal/compliance team.

Next Steps

• Sukhi Jagpal's continued service to Sutro Biopharma, Inc. is required for the stock options to vest according to the monthly schedule.
• The options can be exercised at any time after vesting and before the expiration date, provided the stock price is favorable.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to an existing director as part of their compensation package. It does not contain any new material information regarding Sutro Biopharma's operational performance, financial health, or strategic outlook that would warrant a change in investment recommendation. The transaction is a standard practice to align director incentives with long-term shareholder value, and therefore, a 'hold' recommendation is appropriate as it does not alter the fundamental investment thesis.

Keywords

Sutro Biopharma, STRO, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting